Review
Accepted on 24 Dec 2024
Wnt/β-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1456959
Type at least 3 characters
1,789 articles
Articles
Original Research
Published on 24 Dec 2024
PGD2/PTGDR2 signaling pathway affects the self-renewal capacity of gastric cancer stem cells by regulating ATG4B ubiquitination
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1496050
Review
Published on 24 Dec 2024
Diagnostic and therapeutic role of non-coding RNAs regulating programmed cell death in melanoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1476684
Original Research
Published on 24 Dec 2024
The bioinformatics analysis and experimental validation of the carcinogenic role of EXO1 in lung adenocarcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1492725
- 105 views
Original Research
Accepted on 23 Dec 2024
Implication of Fibroblast Growth Factor 7 in Ovarian Cancer Metastases and Patient Survival
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1524606
Original Research
Accepted on 06 Dec 2024
Small-molecule MMRi36 Induces Apoptosis in p53-mutant Lymphomas by Targeting MDM2/MDM4/XIAP for Degradation
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1462231
- 112 views
Systematic Review
Published on 20 Dec 2024
Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1507608
- 347 views
Correction
Accepted on 19 Dec 2024
Shimizu, Toshio et al. “First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.”
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1544394
Original Research
Accepted on 18 Dec 2024
Deciphering the Oncogenic Network: How C1QTNF1-AS1 Modulates Osteosarcoma Through miR-34a-5p and Glycolytic Pathways
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1485605
Review
Accepted on 17 Dec 2024
ADVANCES AND CURRENT CONCEPTS ON EPH RECEPTORS AND EPHRINS IN UPPER DIGESTIVE TRACT CANCERS
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1520306
Case Report
Published on 17 Dec 2024
A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1467722
- 299 views
Original Research
Published on 17 Dec 2024
Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1508715
- 232 views
Systematic Review
Accepted on 16 Dec 2024
Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers：a systematic review and meta-analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1515992
Review
Published on 16 Dec 2024
Unraveling IFI44L’s biofunction in human disease
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1436576
- 234 views
Original Research
Published on 16 Dec 2024
Hyaluronic acid–targeted topotecan liposomes improve therapeutic efficacy against lung cancer in animals
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1520274
- 221 views
Review
Accepted on 20 Nov 2024
Research progress and treatment status of Malignant Ascites
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1390426
- 124 views